Actavis documents ANDA to market Propofol Injection Actavis, Inc nizagara . today confirmed that it provides filed an Abbreviated New Drug Software with the U.S. Food and Medication Administration seeking authorization to market Propofol Injection 10mg/mL. Fresenius Kabi USA, On June 6 LLC filed suit against Actavis, 2013, in the U.S. District Courtroom for the District of Delaware wanting to prevent Actavis from commercializing its ANDA item prior to the expiration of particular U.S. Patents. Related StoriesMylan announces U.S. Release of generic AXERT tabletsMylan announces U.S.S. Sales of approximately $212 million relating to IMS Health data.